The document goes on, There have recently been suggestions that even the lower figure for HIV numbers in Africa is too high, and that the real figure may be as much as 25% lower. Downward revisions in estimated prevalence rates arise chiefly because of the revision of assumptions about the representativeness of data sources used for estimating national prevalence rates. For example, HIV rates in small towns are typically higher than in villages, but data from antenatal clinics in small towns have often been used as the basis for assessing rates in rural areas, which leads to overestimation. As population-based methods for measuring HIV prevalence are becoming more common, prevalence estimates are usually reduced. However, there are serious methodological difficulties with population surveys, in particular because of the relatively large number of individuals who refuse to provide a sample. Until assessment methodologies are improved, there will remain a high level of uncertainty about prevalence estimates. (5) GAIN concludes that 'it is important to listen carefully to the statisticians, who always insist that it is impossible to know the exact number of people living with HIV and AIDS, and that the best use for surveillance statistics is to identify trends over time rather than "correct" prevalence levels'. (6) AIDS drugs are expensive: this is partly because of royalties that must be paid to patent holders under the TRIPS Agreement and Kenya's Industrial Property Act, 2001,(7) but also because of limited research and development (R and D) on diseases affecting Kenyans. Nongovernmental organizations (NGOs) such as Médecins Sans Frontières (MSF), Action Aid and other health campaigners have argued that more than 50% of Kenyans live on US$1 a day and cannot afford the expensive antiretroviral (ARV) drugs or to maintain optimal nutrition levels associated with effective drug use. Following calls by experts throughout the 1990s, the Industrial Property Act has finally been amended to allow for the parallel importation of generics from India, Brazil and other countries. (8) There have also been controversies regarding compulsory licensing. First, many stakeholders argue that Kenyan firms do not have the capacity to manufacture or distribute such drugs. Second, NGO activists and others argue that the pharmaceutical industry in Kenya is largely oligopolistic and firms have not been keen to process drugs under a compulsory licence. Third, accessing AIDS drugs has revealed more serious health policy problems: even non-patented drugs have not been easily accessible, or they have expired in the central storage facilities, or they have been pilfered through rent-seeking Ministry of Health bureaucrats.
II. The local and external players and their roles back to top
The Kenyan government's position on patents has been that intellectual property rights should be exercised for the mutual benefit of rights holders and consumers. According to Mboi E. Misati, a senior patent examiner at the Kenya Industrial Property Institute (KIPI), 'the TRIPS Agreement should ensure a balance of the rights and the duties of the rights holders vis-à-vis the poor'.(9) Kenya has also argued that the TRIPS Agreement should reflect the socio-economic development of Kenya and other developing countries; that the TRIPS Council should work closely with all stakeholders in order to ensure that the TRIPS Agreement is not in conflict with the public interest, including public health. Kenya's main areas of concern include access to medicines to address public health and nutrition, and its position has been to encourage patent protection but to relax the law to facilitate research and development.(10) The relaxation should be exercised so that it does not infringe the rights of the patent holder. (11) The key negotiators have also played a key role in advancing these concerns. Kenya, South Africa, Malawi and Lesotho started a campaign within the WTO to relax patent protection on drugs. Activists and other players observe that this campaign was successful because they worked closely with other governments. NGOs claim credit for helping developing countries frame policies on the initiatives while also lobbying policy-makers in the European Union (EU) and the United States, where major pharmaceutical companies were based. For instance, activists advised the South African government on its Medicines Act. In February 1999, US campaign members proposed adding provisions to African trade legislation to cut off funding to agencies that pressed African countries to adopt intellectual property laws exceeding the requirement of the TRIPS Agreement. (12) Developing country negotiators were also reportedly well briefed and qualified. NGOs worked closely with the southern African states as they advocated a new essential medicine strategy as a means to counter US and EU trade pressure on patent issues. Dr Olive Shisana, the key negotiator for the African countries, was reportedly tough and well informed.(13) Generic manufacturers also made a difference; pharmaceutical companies in developing countries have also played a critical role in the process. For instance, India's Cipla offered generic substitutes for HIV drugs which would cost US$350 a year for the treatment. This is a small fraction of the price charged by Western firms holding patents on the drugs.
Pressure from developing countries placed the issue of public health on the agenda of the Doha Ministerial Conference. Article 1 of the Doha Declaration recognizes the gravity of health problems afflicting developing countries, including AIDS, malaria and tuberculosis. Article 6 empowered the Council to find an expeditious solution by the end of 2002. (14) There were many formal and informal sessions to execute this mandate. (15) Various problems were recognized in the TRIPS Agreement as identified by the African Group of which Kenya has been a leader.
1. The first impediment was that Article 31(f) of the TRIPS Agreement restricts the use of compulsory licensing to authorising 'predominantly for the supply of the domestic market of the member authorising such use'. This means that a country making use of a compulsory licence must manufacture the product locally for the domestic market. Thus, the country must have sufficient local manufacturing capacity. This is not the case in most of the developing countries. There are three main problems: (i) Kenya and many other developing countries argue that they are too poor to set up factories and they lack sufficient local manufacturing capacity; (ii) the domestic market is too small to attract sufficient investment in the pharmaceutical sector; and (iii) if the domestic market cannot be expanded, economies of scale cannot be achieved. 5. According to some, this waiver should be revised to be an actual amendment rather than an interim measure which can be repudiated at any time. There should be a permanent change to the provision to provide for certainty, since pharmaceutical companies need some certainty before they can invest in the industry. (18) 6. Some members have proposed that Article 30 of the TRIPS Agreement be interpreted broadly to give WTO members the right to allow production without the consent of the patent holder to address public health needs in another country. (19) 7. The first comprehensive decision was given in the Perez Motta text.(20) It was unsatisfactory to Kenya and other developing countries as it did not tackle most of the problems. In the course of rejecting it, the chairman of the African Group(21) expressed disappointment and frustration, saying that the Decision was neither a practical solution nor was it workable. He described it as a step back from Doha.
In a speech read by the African representative,(22) the African Group stated:
The African Group is disappointed and frustrated by the progress made so far. The group feels if the discussions continue on the same line as they have been conducted to date, then it is unlikely that the desired solution will be forthcoming, and particularly one meant to address the public health problems afflicting Africa. Therefore, the Kenya Coalition on Access to Essential Medicines encourages the Kenyan government and UNAIDS to recognize that although there could be short-term benefits from the deal, these could be outweighed by negative consequences in the long run, unless serious efforts are made to stimulate generic production of antiretroviral drugs by local manufacturers and/or to import inexpensive drugs. The introduction of generic drugs will increase competition and will lead, according to general market rules, to considerable price reductions. (28) III. Challenges faced and the outcome back to top
Many players focused on legal provisions: patents. They lobbied the government and the National Assembly to facilitate legislative reform. They also convened fora to condemn the WTO, TRIPS, and pharmaceutical transnational corporations (TNCs). The process of coming up with a comprehensive Industrial Property Act on the issues was also characterized by intense lobbying. In a press conference in 2001 the Coalition for Access to Essential Medicines warned the government of the possibility of powerful pharmaceutical companies using 'not too transparent' ways to woo MPs to vote against a Bill aimed at facilitating access to cheaper medicines. (29) Dr Chris Ouma, Action Aid's national co-ordinator, HIV/AIDS Programme Kenya, argued that
MPs should think about the plight of their people. The rights under the patent shall not extend to acts in respect of articles which have been put on the market in Kenya or in any other country or imported into Kenya by the owner of the patent or with his express consent.
The words in italics were added through an amendment a month after the Act was passed.(32) There was extensive lobbying against this provision by NGOs that believed that it did not sufficiently limit the rights of a patent holder. According to the Kenya Coalition on Access to Essential Medicines, a lobby group bringing together several local and international NGOs in Nairobi,(33) the contentious amendment is especially troubling because it was introduced just a month after the 2001 Industrial Property Act was enacted. (34) We are shocked that the amendment to an Act, which we were involved in, was drafted and passed without the consultation of any of the stakeholders in the civil society … it seems some of the important gains that the IPA [brought about] have now been taken away. (35) In December 2001 Kenya's Assistant Minister for Trade and Industry, Albert Ekirapa, explained to an enraged National Assembly that his ministry had not given a commencement date because the Attorney General's office had not drafted subsidiary regulation to govern its implementation six months after it had been passed. The same office, however, took less than a month to draft the amendment. Partly because of this controversy, the amendment was withdrawn(36) and the Act was reinstated to its original condition. The Industrial Property Act also provides for government use under s. 80.
The first applicant for a licence was Cosmos Industries. It sought to be allowed to produce a drug, the product of Glaxo SmithKline and The Minister also cited the constitutional protection of property in the context of access to HIV/AIDS drugs:
Our Constitution also provides for the sanctity of property and the government indeed respects the Constitution, being the supreme law of the land. Similarly, the government has a duty to provide for easy access to antiretroviral drugs to its citizens who are living with HIV/AIDS, more so when the AIDS pandemic was declared a national disaster. (40) Dr Kituyi then addressed the immediate stakeholders in the licence transaction:
I am therefore very grateful to the two parties, Glaxo SmithKline and Cosmos, who negotiated and agreed on acceptable terms for a voluntary licence. It is my hope that many other pharmaceutical companies in Kenya will follow this noble example to enable the people living with HIV/AIDS to easily access antiretroviral drugs. Once again, Kenya has taken the lead in this region and I am glad to note that the territory referred to in the voluntary licence includes Kenya, Uganda, Tanzania, Burundi and Rwanda. (41) The Minister was optimistic about the impact of the licensing arrangement, and about KIPI's role in the administration of intellectual property:
It is my hope that this function will mark the beginning of a truly healthy competition in the manufacture of not only antiretroviral drugs but all other health drugs in the country for the benefit of all. This will certainly have the ripple effect of creating the much needed wealth in Kenya. Finally let me also take this opportunity to thank KIPI for the role it has played in the negotiations between the two parties here and the eventual registration of the voluntary licence as one of the Institute's mandate under the Industrial Property Act, 2001. My ministry is keen to see all its departments carry out their mandates as provided for under the respective legislations. (42) Another problem identified in Kenya is that the influx of generics may lead to an influx of counterfeit drugs. KIPI has devised some rules for identifying a counterfeit, which it defines as a pharmaceutical product availed to the market or presented to it and intentionally tailored to derive and ride on the reputation or goodwill of another good through labelling or marking. 'The counterfeits are not necessarily substandard goods. But they infringe the patent. Goods are counterfeits when a person other than the owner of the patent makes them without the patentee's licence.' (43) Significantly, there is widespread ignorance in Kenya on the importance of intellectual property rights. Local manufacturing companies are generally afraid to invest in compulsory licensing or parallel importation for fear generally of taking on the pharmaceutical giants.(44) They do not actually realize that they have the legal backing to do so. Even trained lawyers do not actually commit enough time on the complex and wide area of intellectual property.
Beyond the patent debate back to top The Doha and the UNGASS declarations have opened the way to decide about the future of Africa, so, when is your action? The Doha declaration on health is hope, and it must be implemented. Two years ago, the Abuja declaration promised 15% of the budget on health but up to now that has not happened. How many people must die? Please, move from talks to real action. I also want to address the WHO. WHO has promised to give technical assistance in the procurement of drugs. Now we need your assistance in our countries to ensure that cheaper generic drugs reach every country, with or without manufacturing capacity.
You also have a key role in ensuring resources for poor countries. The 3 by 5 initiative should also ensure that all treatment programmes include treatment literacy efforts. On our side, we commit ourselves in educating our people and ensuring adherence. We need real leadership in the implementation of effective strategies to reach the 3 by 5 target. We will assist you in this effort if you show commitment and independence in prioritizing people's health over any other interest. I want to refer to the drug companies, whose bags are full with profits. Stop squeezing poor Africans which only represent 1.3% of your global market. Don't delay access by giving exclusive licenses that are only transferring the monopoly to local companies blocking competition. Your diagnostics are still too expensive and inaccessible. Provide low prices and allow our governments to bring us life-saving essential drugs and the essential monitoring systems. (49) Government procurement of drugs, which is not constrained by the WTO, the TRIPS Agreement or the Industrial Property Act, 2001, is largely inefficient. It further illustrates the policy defects highlighted in the foregoing appeal.
There is limited support for research and development, a matter that has arisen with regard to about five announcements of alleged breakthroughs in AIDS drug development. These 'patent races' or 'wars' include Kemron, Dr 'Stone's' 'Ozone therapy', collaboration between the Universities of Nairobi and Oxford, and the work of Professor Arthur Obel.
Obel developed Pearl Omega, which was challenged by the medical profession and the Kenya AIDS Society (KAS) for, inter alia, not conforming to standards under Kenya's health law and policy regarding clinical testing, efficacy, approval and registration of new drugs. (50) KAS went to court(51) and claimed that its members (patients) would be harmed, and that Obel's representation that he had found a cure could be counter-productive, as there might be recklessness based on false hope. Justice Gideon Mbito upheld Obel's right to process and distribute the drug, thus making important pronouncements on the policy of AIDS research: Obel had taken great personal risks in researching a dangerous disease. Such researchers need incentives. The Court of Appeal(52) upheld the decision (also on a technicality), partly because patients' suffering was alleged but not proved.
Issues regarding incentives and intellectual property have invariably arisen in the five major AIDS drugs announcements. In Kemron there were two major contests of ownership and control. The first pitted the Kenya Medical Research Institute (KEMRI) (or scientific researchers) against traditional healers and herbalists, who claimed a share because they had allegedly contributed biological materials ( Other non-IP strategies that can facilitate access to AIDS drugs in Kenya back to top 1. Therapeutic value pricing. This has been adopted mostly in Australia. The buyer or the state Pharmaceutical Benefit Scheme determines the drug price based on therapeutic value. When a new drug becomes available, they examine it and if it is an improvement on the original, they may allow it to be sold at, say, 10% more.
2. Pooled procurement. For small economies, whereby several countries combine to purchase drugs together, this procedure may be of immense value. In the Caribbean it has halved the prices of drugs. Kenya can try using this through the regional trade arrangements established under the East African Community (EAC) and the Common Market for Eastern and Southern Africa (COMESA).
3. Negotiated procurement. This is where large organizations such as WHO buy drugs in large quantities. In doing so they get huge discounts from the pharmaceutical companies. WHO and WTO member states can derive enormous advantages from this. Concerted international procurement efforts on vaccines and contraceptives have reduced the prices of some drugs. For example, the price of the oral polio vaccine which is sold to developing countries at 33.3 times lower than to the US government. Likewise, the oral contraceptive prices are 130-240 times lower in poor countries than in the United States. The same could be negotiated for antiretrovirals. 5. Government commitment. The commitment shown by the Brazilian and Indian governments in the campaign for access to drugs is overwhelming. If the Kenya government were to exhibit such commitment the question of access to drugs would be significantly improved.
The former South African President, Nelson Mandela, has persuasively argued that an effective strategy for combating the AIDS problem requires the engaged commitment of national leaders to provide not only for prevention but also for anyone who needs drugs 'wherever they may be in the world and regardless of whether they can afford to pay or not'. (57) Kenya has shown some commitment by setting up an anti-Aids campaign dubbed TOTAL WAR ON HIV/AIDS; President Kibaki chairs the committee. (58) In January 2004, Charity Ngilu, the Minister of Health, met with various NGOs and interest groups to get their support, which she did, on the fight at grass-roots level.
The government has also committed itself to fighting AIDS through the AIDS Bill,(59) s. 19 of which commits the government to ensuring that everyone who needs to gets access to AIDS drugs. (60) Remarkably, in 2004 the price of ARVs in public hospitals became as low as KSh 500 a month, down from KSh 6000 a month only a year previously and available in private hospitals only. The government's policy on prevention through condoms and family life education has been weak. It imported condoms in an effort to reduce the rate of infections, against a backdrop of protests by a section of the Catholic Church who for a long time argued that condoms and family life education would encourage promiscuity.
According to one Catholic activist, Condoms are also promoted in Kenya as barriers against STDs [sexually transmitted diseases]. This is despite the countless STDs condoms cannot prevent. These include HPV, which causes genital warts and cancer of the cervix. This is a deadly cancer, very common in Kenya, especially among poor, malnourished, and disadvantaged women. Screening for this cancer is not practical because the health sector has been moribund for a long time. Other STDs condoms cannot prevent include clamydia, which causes sterility, Hepatitis B and C which cause pain and liver cancer, Herpes genitalis, chancroid, and syphilis. Most of these diseases are incurable: the consequences on those treatable are permanent. Condom users are not aware of these facts; those who distribute them dishonestly withhold this information. Since condoms prevent neither HIV nor STDs, those who promote them do so to make blood money as they sacrifice helpless uninformed Kenyans. How do you make informed decisions and informed choice without information? When leaders pass the message that it is all right to be immoral as long as you use a condom, promiscuity increases and AIDS spreads. Asking Kenyans to use condoms is tantamount to sentencing them to death. But even if condoms were 100% protective, their use would still be illicit and below the dignity of the human person created in the image of God. (61) 6. Differential or dynamic pricing. Pharmaceutical companies could charge less for developing countries than in developed countries. This is consistent with the TRIPS Agreement and is backed by, among others, WHO, the EU, MSF and some corporations. The main problems now include preventing the drugs from 'leaking' back to the developed countries, and convincing the citizens of developed countries to be taxed more for the benefit of the poor. (62) IV. Lessons for others: the players' views back to top
As already mentioned, some of the players have indicated that the problem of access to AIDS drugs is more complex, and does not only implicate patents or the WTO. Other problems include inefficient resource allocations, poverty and distribution problems, as well as government policy on public health and patents.
Significantly, the WTO agreed that the TRIPS rules be implemented by 2006. India and other countries which have been providing Kenya with drugs may stop doing so.
In August 2004 WHO delisted some of the generic drugs used for AIDS treatment, arguing that the test to determine their efficacy was conducted in dubious laboratories.(63) This is seen as a backward step, since some Kenyans depend on a particular drug, Rabanoxyl, an Indian product, which is a combination drug consisting of several individual drugs. The individual drugs, which are patented, cost a lot more when used individually. There are new drugs which experts insist are more effective, but the newer the drug the more expensive and the harder for poor Kenyans to obtain.
Activists opposed to the patenting of AIDS drugs have been criticized a lot. At the thirteenth ICASA conference, they characteristically joined in the protest. Kenya should learn to invest in research and development, and national health law and policy as well as patent law, all of which have affected AIDS research and development.
The effort to combat HIV/AIDS must not be handled in the traditional manner of tying foreign aid to politics. Kenya must act with a sense of urgency and purpose and approach the battle against HIV/AIDS with the same resolve and commitment that the world is using to fight terrorism. Towards this goal Kenya requires leadership and local and international co-operation. Shifting goalposts and blaming non-critical factors such as patents, the Industrial Property Act, 2001, TRIPS and the WTO is not terribly helpful. Efficient policy, legal, institutional and administrative reforms of public health, research and development and patent law are all important. Researcher Anna Coutsoudis startled her colleagues at the thirteenth International AIDS Conference in Durban, South Africa, with the following information: in a study of 551 mother-and-child pairs, first published in the prestigious peer-reviewed journal The Lancet (7 Aug. 1999), her group found that mothers who breastfed their babies for at least three months had no more chance of transmitting HIV to their children than mothers who never breastfed at all. Even more surprising, children who received a mixed diet of formula and breast milk had the highest HIV rates over a period of six months. Coutsoudis followed these children for more than fifteen months, and the results remained the same. 
